Memphasys Sharpens Focus as Felix™ Commercialisation Gains Pace
Memphasys (ASX: MEM) has pulled in fresh funds to accelerate the rollout of its Felix™ sperm selection system, completing a placement worth $840,000 and launching a non-renounceable rights issue to raise up to $1.12 million. Shares were issued at 0.3 cents, a 36 per cent discount to the recent five-day VWAP, with investors also offered one free option for every four shares subscribed, exercisable at 1.1 cents until November 2026.
Felix™ console and cartridge
The placement drew strong support from existing shareholders and new backers alike. Non-Executive Director Marjan Mikel is also set to chip in $20,000 of his own money, pending shareholder approval.
From Burn to Build – Costs Cut by 40%
Alongside the raise, management revealed a drastic rationalisation of operations, slashing annual operating costs from about $3 million to $1.8 million in 2026. Rather than simply banking the savings, the company is redeploying funds into scaling Felix™ manufacturing, stockpiling inventory, and targeting gross margins with a sub-$40 cost per cartridge.
Chairperson Lindley Edwards called the strategy “a disciplined, commercial focus” aimed at converting the company’s R&D heritage into a revenue-generating enterprise.
Contracts in Hand, Markets in Sight
Memphasys is already delivering on its expanded $390,000 agreement with International Test Laboratories, which now extends into Turkey and represents the company’s first contracted EU revenues. Negotiations are also underway in Japan, India and New Zealand, with “volume-based agreements” flagged for the coming quarters.
At the same time, Memphasys is progressing CE Mark certification, the regulatory gateway to Europe’s IVF market – the largest globally. Management is banking on early contracts to create the production volume needed to drive down costs and reinforce its razor/razorblade model.
Investor Sentiment Turning Positive
For years, Memphasys has been criticised for spreading its attention too broadly. Investors now appear to be responding favourably to the tighter focus. According to the company, institutional and strategic backers have praised the sharpened pathway, applauding both the cost discipline and the redeployment of funds into production.
Edwards said:
“With funding secured, we are executing binding contracts, advancing new deals, and scaling manufacturing to drive costs down. Further, we’ve cut operating expenses some 40% and redeployed savings into production and inventory, targeting margins of less than $40 per cartridge. This disciplined, commercial focus sets the foundation for sustainable revenues and long-term shareholder value.”
The Road Ahead
FY2026 is shaping up as a pivotal year for Memphasys. If the company can land its pending deals and deliver product at scale, it may finally move from being seen as a clever lab innovator to a revenue-driven medtech player. IVF clinics, however, will need to be convinced that Felix™ can become the new benchmark for sperm selection in a competitive field.
For now, Memphasys has bought itself time and flexibility. The capital raise and cost cuts provide the runway, but the true test will come in turning contracts into invoices and invoices into cash flow.